These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34446301)

  • 1. Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology.
    Ehlers JP; Yeh S; Maguire MG; Smith JR; Mruthyunjaya P; Jain N; Kim LA; Weng CY; Flaxel CJ; Schoenberger SD; Kim SJ
    Ophthalmology; 2022 Jan; 129(1):88-99. PubMed ID: 34446301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology.
    Yeh S; Kim SJ; Ho AC; Schoenberger SD; Bakri SJ; Ehlers JP; Thorne JE
    Ophthalmology; 2015 Apr; 122(4):769-78. PubMed ID: 25576994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapies for Macular Edema Associated with Branch Retinal Vein Occlusion: A Report by the American Academy of Ophthalmology.
    Ehlers JP; Kim SJ; Yeh S; Thorne JE; Mruthyunjaya P; Schoenberger SD; Bakri SJ
    Ophthalmology; 2017 Sep; 124(9):1412-1423. PubMed ID: 28551163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology.
    Ho AC; Scott IU; Kim SJ; Brown GC; Brown MM; Ip MS; Recchia FM
    Ophthalmology; 2012 Oct; 119(10):2179-88. PubMed ID: 22917890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
    Hussain RM; Ciulla TA
    Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration: A Report by the American Academy of Ophthalmology.
    Bakri SJ; Thorne JE; Ho AC; Ehlers JP; Schoenberger SD; Yeh S; Kim SJ
    Ophthalmology; 2019 Jan; 126(1):55-63. PubMed ID: 30077616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
    Krick TW; Bressler NM
    Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants in Initial Treatment Choice for Diabetic Macular Edema.
    VanderBeek BL; Scavelli K; Yu Y
    Ophthalmol Retina; 2020 Jan; 4(1):41-48. PubMed ID: 31345726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema.
    Wykoff CC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4):308-12. PubMed ID: 27065368
    [No Abstract]   [Full Text] [Related]  

  • 13. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
    Cai S; Bressler NM
    Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Noninfectious Uveitic Macular Edema with Periocular and Intraocular Corticosteroid Therapies: A Report by the American Academy of Ophthalmology.
    Smith JR; Thorne JE; Flaxel CJ; Jain N; Kim SJ; Maguire MG; Patel S; Weng CY; Yeh S; Kim LA
    Ophthalmology; 2024 Sep; 131(9):1107-1120. PubMed ID: 38647511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.
    Wood EH; Karth PA; Moshfeghi DM; Leng T
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.
    Rahimy E; Shahlaee A; Khan MA; Ying GS; Maguire JI; Ho AC; Regillo CD; Hsu J
    Am J Ophthalmol; 2016 Apr; 164():118-27.e2. PubMed ID: 26748058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
    Glassman AR; Wells JA; Josic K; Maguire MG; Antoszyk AN; Baker C; Beaulieu WT; Elman MJ; Jampol LM; Sun JK
    Ophthalmology; 2020 Sep; 127(9):1201-1210. PubMed ID: 32402554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study.
    Shimura M; Kitano S; Muramatsu D; Fukushima H; Takamura Y; Matsumoto M; Kokado M; Kogo J; Sasaki M; Morizane Y; Kotake O; Koto T; Sonoda S; Hirano T; Ishikawa H; Mitamura Y; Okamoto F; Kinoshita T; Kimura K; Sugimoto M; Yamashiro K; Suzuki Y; Hikichi T; Washio N; Sato T; Ohkoshi K; Tsujinaka H; Kusuhara S; Kondo M; Takagi H; Murata T; Sakamoto T;
    Br J Ophthalmol; 2020 Sep; 104(9):1209-1215. PubMed ID: 31784500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in a Real-World Clinical Setting.
    Maggio E; Sartore M; Attanasio M; Maraone G; Guerriero M; Polito A; Pertile G
    Am J Ophthalmol; 2018 Nov; 195():209-222. PubMed ID: 30098350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients.
    Ruiz-Moreno JM; de Andrés-Nogales F; Oyagüez I
    BMC Ophthalmol; 2020 Sep; 20(1):371. PubMed ID: 32943041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.